STRIVERDI RESPIMAT
LABA SMI
Olodaterol · Boehringer Ingelheim
Active Medication & Mechanism
- Olodaterol hydrochloride LABA2.5 mcg per actuation
Long-acting beta2-adrenergic agonist. Selectively stimulates beta2-receptors on airway smooth muscle, increasing intracellular cAMP and producing sustained bronchodilation (~24 hours).
FDA-Approved Dosing by Indication
// approval varies by strength + age COPD
1/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| 2.5 mcg | Adults (≥18 years) | 2 puffs (5 mcg total) once daily at the same time each day Long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. | 5 mcg | FDA Approved |
Asthma
0/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| Any strength | All patients | — | — | Not Approved Striverdi is NOT indicated for asthma. LABA without ICS increases risk of serious asthma events. |
Acute Use
0/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| Any strength | Acute bronchospasm / rescue | — | — | Not Approved Not for acute bronchospasm. Use a SABA. |